ClinicalTrials.gg
CompletedNCT01686633Updated Jan 24, 2018Results posted

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

A Phase 3 interventional study of Fluticasone Furoate/ Vilanterol 200/25 mcg and Fluticasone Furoate/ Vilanterol 100/25 mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 137 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,040
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
3rd of 40
1,040 · median 102
Started
2012
with 1 other
Phase 3
14 of 40
none open now
Registered
24th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 3rd largest by enrollment, is one of 2 that started in 2012, is one of 14 in phase 3, and was the 24th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma. The study consists of a run-in period of 4 weeks, followed by a treatment period of 12 weeks, and a follow up contact period of one week. The total duration of the study is 17 weeks. 990 subjects will be randomized to one of three treatments (FF/VI Inhalation Powder 200/25 mcg once daily in the evening; FF/VI Inhalation Powder 100/25 mcg once daily in the evening; FF 100 Inhalation Powder once daily in the evening) for 12 weeks. In addition, all subjects will be supplied albuterol/salbutamol inhalation aerosol at Visit 1 to use as needed for acute asthma symptoms throughout the entire study. Subjects will attend four on-treatment visits at Weeks 2, 4, 8, and 12 (Visits 4 through 7).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • pharmacogenetics
  • adult
  • vilanterol
  • adolescents
  • fluticasone furoate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must give their signed and dated (written) to participate. Written informed consent must be obtained if a subject's current medication is changed as a result of study participation
  • Outpatient >=12 years of age at Visit 1 who have had a diagnosis of asthma, as defined by the National Institutes of Health. Countries with local restrictions prohibiting enrolment of adolescents will only enroll subjects >=18 years of age
  • Male or an eligible female. Eligible female is defined as having non- or having childbearing potential and using an acceptable method of consistently and correctly.
  • Best pre-bronchodilator of 40% to 80% of their predicted normal value.
  • Demonstrate >=12% and >=200 mL reversibility of FEV1 within 10 to 40 minutes following 4 inhalations of albuterol/salbutamol inhalation aerosol (or an equivalent nebulized treatment with albuterol/salbutamol solution) or have documented reversibility testing within the 6 months prior to Visit 1 meeting this measure of reversibility. A spacer device may be used for testing, if required.
  • If subject have received ICS for at least 12 weeks prior to Visit 1 and their treatment during the 4 weeks immediately prior to Visit 1 consisted of either of the two regimens (a or b).a.) A stable mid-dose or high-dose of ICS alone (e.g., >=FP 250 mcg twice daily) or b.) A stable dose of a mid-dose ICS/LABA combination (e.g., FP/Salmeterol [SALM] 250/50 mcg twice daily) or an equivalent combination via separate inhalers.
  • Use of ICS/LABA are not permitted with LABA on the day of Visit 1.
  • Must be able to replace current SABA treatment with albuterol/salbutamol aerosol inhaler at Visit 1 for use as needed, during the study. Subjects must be able to withhold albuterol/salbutamol for at least 6 hours prior to study visits

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years.
  • Upper or lower respiratory tract, sinus, or middle ear that is: not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the investigator, expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any asthma exacerbation that required oral within the 12 weeks prior to Visit 1 or, resulted in an overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  • A subject must not have current evidence of atelectasis (segmental or larger), bronchopulmonary dysplasia, , Or any evidence of concurrent respiratory disease other than asthma
  • A subject must not have any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study
  • Chronic stable or C are acceptable provided their screening (ALT) is \<2x (ULN) and the y otherwise meet the entry criteria. Chronic co-infection with both hepatitis B and are not eligible
  • Clinical visual evidence of candidiasis at Visit 1
  • Use of any drug within 30 days prior to Visit 1 or within five half-lives (t½), whichever is longer of the two.
  • Allergies to drug or milk protein: any adverse reaction, to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy or known or suspected sensitivity to the constituents of the NDPI, or history of severe milk protein allergy
  • Administration of medication that would significantly affect the course of asthma, or interact with study drug
  • Use of medications during the study.
  • Use of potent inhibitor within 4 weeks of Visit 1.
  • A subject or his/her parent or legal guardian has any infirmity, disability, disease, or resides in a geographical location which seems likely, in the opinion of the Investigator, to impair compliance with any aspect of this study protocol, including visit schedule, and completion of the daily diaries.
  • Current smoker or has a smoking history of 10 pack-years (20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 3 months (i.e., cigarettes, cigars, or pipe tobacco).
  • If subject is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
  • Subject previously randomized to treatment with FF/VI or FF in another Phase III study
  • Subjects working on night shift a week prior to Visit 1 or during the study period.
  • Adolescents who are wards of the state or government
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
1,040 participants (actual)

Study arms

  • Experimental
    Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg

    At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.

    Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg

  • Experimental
    Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg

    At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days

    Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg

  • Experimental
    Arm 3: Fluticasone Furoate 100 mcg

    At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days

    Drug: Fluticasone Furoate 100 mcg

Interventions

  • DrugFluticasone Furoate/ Vilanterol 200/25 mcg

    Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation

  • DrugFluticasone Furoate/ Vilanterol 100/25 mcg

    Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation

  • Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 (within 30 minutes prior to dosing) and post-dose FEV1 measurements at 5, 15, and 30 minutes and at 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours on Day 84/Week 12. At each time point, the highest of three technically acceptable measurements was recorded. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 84/Week 12 minus the Baseline value. Baseline was the pre-dose FEV1 measurement value obtained at Visit 3. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline FEV1, region, sex, age, and treatment.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Clinic Visit Trough FEV1 at the End of the 12-week Treatment Period

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on-treatment. Change from Baseline in trough FEV1 at the end of the 12-week treatment period was defined using the 24-hour post-dose serial FEV1 measurement taken at the Week 12 clinic visit. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

    Time frame: Baseline and Week 12

  2. Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

    The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  3. Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

    Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  4. Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

    Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use and each morning. The best of three measurements was recorded. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  5. Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use and each morning. The best of three measurements was recorded. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

07

Results

Posted Jun 6, 2014

Participant flow

Participants meeting eligibility criteria at the Screening visit entered a 4-week Run-in Period for Baseline safety evaluations and measures of asthma status. Participants were then randomized to a 12-week Treatment Period. A total of 2019 participants were screened; 1039 were randomized and received \>=1 dose of study treatment.

Participant flow — Overall Study
MilestoneFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Started347346346
Completed296314321
Not completed513225
Withdrew: Lack of efficacy331311
Withdrew: Withdrawal by subject885
Withdrew: Physician decision344
Withdrew: Adverse event433
Withdrew: Protocol violation230
Withdrew: Protocol-defined stopping criteria101
Withdrew: Lost to follow-up011

Outcome measures

PrimaryChange From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 (within 30 minutes prior to dosing) and post-dose FEV1 measurements at 5, 15, and 30 minutes and at 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours on Day 84/Week 12. At each time point, the highest of three technically acceptable measurements was recorded. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 84/Week 12 minus the Baseline value. Baseline was the pre-dose FEV1 measurement value obtained at Visit 3. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline FEV1, region, sex, age, and treatment.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period
LitersFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period0.366 ± 0.02310.474 ± 0.02210.499 ± 0.0222
Statistical analysis
  • FF 100 µg OD vs FF/VI 100/25 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 0.108 · 95% CI 0.045 to 0.171
  • FF/VI 100/25 µg OD vs FF/VI 200/25 µg OD · Mean difference (final values): 0.024 · 95% CI -0.037 to 0.086
SecondaryChange From Baseline in Clinic Visit Trough FEV1 at the End of the 12-week Treatment Period

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on-treatment. Change from Baseline in trough FEV1 at the end of the 12-week treatment period was defined using the 24-hour post-dose serial FEV1 measurement taken at the Week 12 clinic visit. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Clinic Visit Trough FEV1 at the End of the 12-week Treatment Period
LitersFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in Clinic Visit Trough FEV1 at the End of the 12-week Treatment Period0.365 ± 0.02200.441 ± 0.02210.457 ± 0.0220
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of rescue-free 24-hr periodsFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period22.6 ± 1.8434.8 ± 1.8535.8 ± 1.85
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of symptom-free 24-hr periodsFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period19.4 ± 1.7427.2 ± 1.7429.0 ± 1.74
SecondaryChange From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use and each morning. The best of three measurements was recorded. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Liters per minute
Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Liters per minuteFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period19.1 ± 2.2544.3 ± 2.2547.7 ± 2.25
SecondaryChange From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use and each morning. The best of three measurements was recorded. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Liters per minute
Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
Liters per minuteFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period15.5 ± 2.2439.7 ± 2.2441.7 ± 2.24

Adverse events

Collected over Serious Adverse Events (SAEs) and non-serious AEs were collected from the first dose of study medication up to Week 12/Early Withdrawal.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 100 µg OD—3/347 (0.9%)67/347 (19.3%)
FF/VI 100/25 µg OD—4/346 (1.2%)54/346 (15.6%)
FF/VI 200/25 µg OD—1/346 (0.3%)52/346 (15%)
Most frequent serious events
Most frequent serious events
EventFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
PneumoniaInfections and infestations2/3470/3460/346
Pancreatitis acuteGastrointestinal disorders0/3471/3460/346
Biliary colicHepatobiliary disorders0/3471/3460/346
Thermal burnInjury, poisoning and procedural complications0/3471/3460/346
Occipital neuralgiaNervous system disorders0/3471/3460/346
Abortion threatenedPregnancy, puerperium and perinatal conditions0/3470/3461/346
Borderline mucinous tumour of ovaryNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3470/3460/346
Most frequent other events
Most frequent other events
EventFF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
HeadacheNervous system disorders32/34729/34629/346
NasopharyngitisInfections and infestations26/34722/34625/346
Upper respiratory tract infectionInfections and infestations12/3478/3467/346

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
Mean44.7 ± 15.8945.9 ± 16.1446.6 ± 14.7245.7 ± 15.60
Sex: Female, Male
Sex: Female, Male(Participants)FF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
Female199205224628
Male148141122411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FF 100 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
African American/African Heritage26202874
American Indian or Alaska Native0022
Asian - East Asian Heritage0101
Asian - Japanese Heritage1001
Asian - South East Asian Heritage3126
Native Hawaiian or other Pacific Islander0101
White - White/Caucasian/European Heritage305307300912
Mixed Race12161341
Missing0011
08

Study locations

137 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Rancho Mirage, California 92270, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    San Diego, California 92103-8415, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63143, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Shelby, North Carolina 28152, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45242, United States
  • GSK Investigational Site
    Middleburg Heights, Ohio 44130, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Fort Mill, South Carolina 29707, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    El Paso, Texas 79903, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Richmond, Virginia 23219, United States
  • GSK Investigational Site
    Seattle, Washington 98122, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1405BCH, Argentina
  • GSK Investigational Site
    Nueve de Julio, Buenos Aires B6500BWQ, Argentina
  • GSK Investigational Site
    San Rafael, Mendoza 5600, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000JKR, Argentina
  • GSK Investigational Site
    Berazategui, 1886, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425FVH, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Tucuman, 4000, Argentina
  • GSK Investigational Site
    Rancagua, Reg Del Libert Bern Ohiggins 2841959, Chile
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500800, Chile
  • GSK Investigational Site
    Quillota, Valparaíso 2260000, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Viña del Mar, Valparaíso, Chile
  • GSK Investigational Site
    Santiago, 8380453, Chile
  • GSK Investigational Site
    Potsdam, Brandenburg 14467, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Berlin, 13086, Germany
  • GSK Investigational Site
    Berlin, 14050, Germany
  • GSK Investigational Site
    Zapopan, Jalisco 45040, Mexico
  • GSK Investigational Site
    Morelia, Michoacán 58070, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64000, Mexico
  • GSK Investigational Site
    Villahermosa, Tabasco 86100, Mexico
  • GSK Investigational Site
    Almelo, 7609 PP, Netherlands
  • GSK Investigational Site
    Breda, 4819 EV, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Enschede, 7513 ER, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Veldhoven, 5504 DB, Netherlands
  • GSK Investigational Site
    Zutphen, 7207 AE, Netherlands
  • GSK Investigational Site
    Bialystok, 15-027, Poland
  • GSK Investigational Site
    Krakow, 30-901, Poland
  • GSK Investigational Site
    Krakow, 31-024, Poland
  • GSK Investigational Site
    Krakow, 31-455, Poland
  • GSK Investigational Site
    Lodz, 90-242, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Warszawa, 02-507, Poland
  • GSK Investigational Site
    Wroclaw, 53-301, Poland
  • GSK Investigational Site
    Bacau, 600114, Romania
  • GSK Investigational Site
    Brasov, 500112, Romania
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 030317, Romania
  • GSK Investigational Site
    Bucuresti, 022102, Romania
  • GSK Investigational Site
    Cluj Napoca, 400370, Romania
  • GSK Investigational Site
    Craiova, 200642, Romania
  • GSK Investigational Site
    Deva, 330084, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
  • GSK Investigational Site
    Pitesti, 110084, Romania
  • GSK Investigational Site
    Ploiesti, 100172, Romania
  • GSK Investigational Site
    Ploiesti, 100184, Romania

Showing the first 100 of 137 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2015;52(10):1073-83. doi: 10.3109/02770903.2015.1056350. Epub 2015 Aug 18. PubMed 26291137 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2012
First posted
Sep 18, 2012
Start
Sep 20, 2012
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 15, 2013
Results first posted
Jun 6, 2014
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01686633
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Sep 20, 2012
Primary completion
Oct 1, 2013
Completion
Oct 15, 2013
Results posted
Jun 6, 2014
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion